Pfizer Inc. (NYSE:PFE) Shares Bought by WCM Investment Management LLC

WCM Investment Management LLC grew its position in Pfizer Inc. (NYSE:PFE) by 8.7% in the first quarter, Holdings Channel.com reports. The fund owned 125,964 shares of the biopharmaceutical company’s stock after buying an additional 10,051 shares during the period. WCM Investment Management LLC’s holdings in Pfizer were worth $3,176,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC boosted its holdings in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC lifted its holdings in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Pfizer by 47.8% in the fourth quarter. Victory Capital Management Inc. now owns 5,152,861 shares of the biopharmaceutical company’s stock valued at $136,705,000 after acquiring an additional 1,666,189 shares during the period. Glass Wealth Management Co LLC grew its holdings in shares of Pfizer by 0.7% during the fourth quarter. Glass Wealth Management Co LLC now owns 104,395 shares of the biopharmaceutical company’s stock valued at $2,770,000 after purchasing an additional 709 shares during the last quarter. Finally, Snider Financial Group acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $362,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on PFE shares. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group increased their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Finally, Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective on the stock. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Stock Performance

PFE stock opened at $25.32 on Thursday. The company has a 50-day simple moving average of $23.62 and a 200 day simple moving average of $24.83. The company has a market capitalization of $143.95 billion, a P/E ratio of 18.35, a PEG ratio of 0.91 and a beta of 0.58. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.82 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.79%. Pfizer’s dividend payout ratio (DPR) is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.